Participant Information Sheet and Informed Consent Form

Study Title: A Randomized Controlled Study To Compare The Safety And Efficacy Of IPX203 With Immediate –Release Carbidopa-Levodopa In Parkinson's Disease Patients With Motor Fluctuations

Protocol No: IPX203-B16-02

Short Title: A Phase 3, Randomized Controlled Study of IPX203

Sponsor: Impax Laboratories, LLC

IRAS No: 259840

Study Doctor: Dr. Steven Allder

Research Site: Re:Cognition Health - London

Research Address: 45 Queen Anne Street, London W1G 9JF

Telephone Number: 020 3355 3536

24 Hour Number: 07540802222

Participant's Name: _____

Participant's Number: _____

1. Introduction

We would like to invite you to take part in this research study because you have Parkinson's disease (PD). This research study is testing how effective IPX203 (an investigational drug containing carbidopa and levodopa) is in helping treat the symptoms of Parkinson's disease and whether it is well tolerated compared to a marketed form of immediate release carbidopa-levodopa (IR CD-LD).

This Participant Information Sheet and Informed Consent Form (PIS-ICF) tells you about the research study, including any benefits and risks. It explains the tests and study drugs involved. Knowing what is involved will help you decide if you want to take part in the research.

Please read this information carefully. Ask questions about anything that you do not understand or want to know more about. Before deciding whether or not you want to take part, you might want to talk about it with a relative, friend or your General Practitioner (GP).

Participation in this research is voluntary. If you do not wish to take part, you do not have to.

If you decide you want to take part in the research study, you will be asked to sign the Informed Consent Form. By signing it you are telling us that you:

- understand what you have read;
- consent to take part in the research study;
- consent to have the tests and study drugs that are described;

- grant a waiver of confidentiality to the doctors and other members of your care team in respect of your confidential personal and health information, but only to the extent strictly necessary for them to fulfil the legal and research purposes described below.

You will be given a signed copy of the Participant Information Sheet and Informed Consent Form to keep.

This study has been reviewed and given a favourable opinion by London - Fulham Research Ethics Committee.

2. What is the purpose of this research?

Parkinson's disease is a degenerative disorder of the central nervous system (the part of the nervous system that consists of the brain and spinal cord). The symptoms of Parkinson's disease result from the loss of dopamine-generating cells in the brain. Dopamine is a chemical released by nerve cells to send signals to other nerve cells. Symptoms of Parkinson's disease can include shaking, stiffness, slowness of movement and difficulty with walking.

Levodopa is a drug primarily used for the treatment of Parkinson's disease and is the most commonly prescribed drug for the control of motor symptoms associated with Parkinson's disease. Levodopa is usually prescribed with other drugs (frequently carbidopa) to slow the rate at which it is broken-down in the body.

IPX203 is an investigational extended-release (i.e. releases drug more slowly) capsule formulation of carbidopa-levodopa (CD-LD) administered orally (by mouth). It is being investigated for its potential as a possible treatment of Parkinson's disease symptoms.

"Investigational" means that IPX203 is being tested and has not been approved for marketing in the United Kingdom by the Medicines & Healthcare products Regulatory Agency (MHRA). IPX203 is being investigated to determine whether the drug is safe and has a better effect than the currently marketed forms of IR CD-LD (e.g. Sinemet). If successful, the drug could possibly improve the daily control of motor symptoms in people with Parkinson's disease.

The aim of this study is to test the safety and efficacy of IPX203 compared to IR CD-LD in participants with Parkinson's disease.

The use of IPX203 in this study is experimental. IR CD-LD is an approved drug for the treatment of Parkinson's disease in the United Kingdom. Be aware that this form refers to both IPX203 and IR CD-LD as "study drug".

This study is being conducted at multiple clinical sites in the United Kingdom, United States, and Europe. The sponsor (the company paying for the study) is Impax Laboratories, LLC and they will be paying the hospital/Research Centre to conduct the study.

3. What does participation in this research involve?

Male and female participants with advanced Parkinson's disease who were at least 40 years old at the time of Parkinson's disease diagnosis may participate in the study.

Approximately 420 participants will take part in this study and receive study drug.

Before you decide if you want to participate in the study, you will be given information about the study drugs being studied, the study, and any other relevant information by the research staff. You will be asked to read and understand this PIS-ICF. You are encouraged to ask questions until you are sure that you fully understand the nature and requirements of the study. If you decide to be assessed for inclusion in the study, you will be asked to visit the hospital for an initial assessment visit (Screening Visit). Before any procedures are undertaken, you will be asked to sign the Informed Consent Form. You will then have some tests to check if the study is suitable for you. The Screening Visit may take between 3 and 4 hours. When results of the examinations performed at this visit are available, the study staff will confirm whether the study is suitable for you.

If the study doctor says you can continue in the study and you want to continue, you will be asked to return to the study site within 30 days of the Screening Visit. At that time, you will receive a 3-week supply of IR CD-LD tablets along with instructions on how and when to take the study drug. The study staff will call you regularly during this 3 week IR CD-LD dose adjustment period to follow up and determine if dose adjustments are needed.

Following this 3-week IR CD-LD dose adjustment period, your study drug will be changed (converted) from IR CD-LD to IPX203 capsules. Your initial dosing of IPX203 will be based on your recently adjusted dose regimen of IR CD-LD. During the next 4 weeks, your dose of IPX203 may then be adjusted to your individual needs. You will be in contact with the study staff (during hospital visits and by phone) during this 4 week IPX203 dose conversion period to discuss if dosage changes are required. At the end of this 4-week IPX203 dose conversion period, your study doctor will determine if you are eligible to continue in the study. If the study doctor says you can continue in the study and you want to continue you will be assigned by chance (like flipping a coin) to 1 of the 2 study groups:

- Group 1: IPX203 and IR CD-LD placebo
- Group 2: IR CD-LD and IPX203 placebo

Placebo looks like the study drug but has no active drug.

You will take IR CD-LD or IR CD-LD placebo as you did at the end of your 3-week dose adjustment period. You will take IPX203 or IPX203 placebo as you did at the end of your 4-week IPX203 dose conversion period. You will take your assigned study drugs for 13 weeks. Ask the study doctor if you have any questions about the study drugs. It is very important that you take the study drugs (tablets and capsules) as instructed. You should take the study drugs with water and do not chew or crush them.

You have an equal chance of being assigned to either of the two study groups. Neither you, nor the study doctor will be able to choose which study group you are in. You will not know and the study doctor will not know which study group you are in, but the study doctor can find out if it is necessary to know for your health. Even if this happens, the study doctor may not be able to tell you which study group you were in until everyone finishes the study (which may be years in some cases).

You are the only one who should take the study drug. You should not give the study drug to anyone else and you should make sure no one else takes it.

If you decide to be in this study, you will have to stop taking any other CD-LD (or benserazide-LD, e.g. Madopar) containing prescriptions that you currently have at home or may receive during the course of this study. Your study drugs contain CD-LD and therefore you should not combine the CD-LD study drugs with any of your CD-LD (or benserazide-LD) prescription medications. CD-LD containing prescription medications include Sinemet, Sinemet CR, Stalevo, and benserazide-LD containing medications including Madopar. You

will be given strict instructions and a schedule of how and when to take your study drug during each phase of the study. You will continue to take your permitted other Parkinson's medications using the same dose and schedule that you used prior to the study. You will continue to take your permitted non-PD medications using the same dose and schedule that you used prior to the study.

IR CD-LD: IR CD-LD will be provided as tablets containing 100 mg LD and 25 mg CD. The initial dose (amount) for IR CD-LD will be based on your usual daily dosing regimen. The study doctor may adjust the IR CD-LD dosing regimen based on your response to the study drug during the first 3 weeks of the study. Your study doctor will instruct you on the dose of IR CD-LD (or IR CD-LD placebo) that you will receive during the 13-week portion of the study.

IPX203: The initial dose (amount) of IPX203 that you receive during the 4-week conversion period will be based on the most frequent IR CD-LD dose that you take each day.

IPX203 is provided as a capsule containing 140 mg LD and 35 mg CD. The study doctor may adjust the IPX203 dosing regimen based on your response to the study drug during the 4 week dose conversion period. Your study doctor will instruct you on the dose of IPX203 (or IPX203 placebo) that you will receive during the 13-week portion of the study.

Your total participation time in the study will be approximately 24 weeks (6 months), which includes 4 weeks for your initial assessment (screening) period to determine if the study is suitable for you.

The following specific procedures will occur at some or all of your study visits:

- **Health and Medication Questions:** You will be asked to answer questions about your health, your medical history, your history with PD, and the medications you take.
- **Physical Examination:** The study doctor will perform a physical examination. You may ask the study doctor about what will happen during this examination.
- **Blood Pressure, Pulse, Breathing, and Temperature:** Your blood pressure will be checked by putting a band around your arm. Your blood pressure and pulse will be taken in both lying down and standing positions.
- **Height and Weight:**
- **Blood Tests:** Blood will be taken to do laboratory tests.
- **Urine Tests**: You will provide urine samples for clinical laboratory tests. Including testing for drugs of abuse (recreational drugs). You are not allowed to take recreational drugs while participating in the study. The study staff will tell you if the urine drug test results are positive. The results of the urine drug tests must be negative in order for you to be in the study.
- **Breath tests for alcohol:** An alcohol breath test will be performed. The study doctor or study staff will tell you if the test results are positive. A positive alcohol breath test will prevent continued participation in the study.
- **Pregnancy Test:** If you are a woman and can have children, you will be asked to have a urine pregnancy test. The study doctor or study staff will tell you if the pregnancy test results are positive. The results of the pregnancy test must be negative in order for you to be in the study.
- **ECG:** An "ECG" or "electrocardiogram" is a test that measures the electrical activity of your heart.
- **Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS):** The study staff will evaluate the severity of your Parkinson's disease

symptoms and any adverse effects of PD treatments that you are currently taking using the MDS-UPDRS. The MDS-UPDRS is an accepted standardised questionnaire that includes some parts of the neurologic motor examination specific for PD.

- **Montreal Cognitive Assessment (MoCA):** The study staff will ask you questions as part of an examination of your cognitive (thinking and memory) function.
- **Columbia-Suicide Severity Rating Scale (C-SSRS).** The study staff will also ask you questions including those regarding suicidal thoughts/attempts that may cause you to feel uncomfortable or upset. This type of scale is required for participant studies of new (investigational) neurologic compounds.
- **Participant Parkinson's disease (PD) Diary:** You will be instructed on how to complete a PD diary. At screening and on Visit 1 and 3-6, you will be given 3 diaries to take home with you and will be asked to record how you feel at home every 30 minutes you are awake in a provided 24-hour diary for 3 consecutive (back-to-back) days immediately prior to these visits to the clinical centre (Visits 1, 2 and 4, 5, 6, and 7).
- You will be asked to bring the completed diaries with you to Visits 1, 2, 4, 5, 6, and 7. Your PD Diary is extremely important to this study and is the main way in which the effectiveness of IPX203 in helping the symptoms of Parkinson's will be judged.3 Therefore, your careful attention to completion of every PD Diary is critical to your continued participation in this study.
- A number of other assessments or questionnaires will be completed as part of this study by you or by the clinical staff.

The study staff can answer any questions you may have about the tests and procedures.

While you are in the study, you must:

- Follow the instructions you are given.
- Come to the study centre for all visits with the study doctor.
- Tell the study staff about any changes in your health.
- Tell the study staff if you want to stop being in the study at any time.

Your GP will be informed that you are participating in this study.

Screening visit [within 4 weeks prior to Visit 1

After reading this Participation Information sheet and Informed Consent Form and you agree to participate in the study, you will be asked to sign the ICF.

Once you have signed the Informed Consent Form, the study doctor will perform an examination to check that it is safe for you to be part of the study. If you would like more information about which tests and procedures will be done at each study visit, ask the study doctor or study staff.

You will be asked about previous medical problems, your current health, your PD history, and any medications you may be taking. Your blood pressure, heart rate, and respiratory (breathing) rate will be taken after you have been lying down for at least 5 minutes. Your blood pressure and heart rate will also be measured after you have been standing for approximately 2 minutes. Your temperature and tracings of your heart rhythm (ECG) will be taken. You will have your height and weight recorded. You will be asked to provide urine sample(s) to assess your general health and to test for recreational drugs. Blood samples will be collected for routine measurements including clinical laboratory safety testing (approximately 2 teaspoons). An alcohol breath test will also be performed.

If you are a woman of childbearing potential, your urine will be collected for a pregnancy test.

Your study doctor or a member of the study staff will assess your Parkinson's disease symptoms using standard scales called the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS). In addition, the Montreal Cognitive Assessment (MoCA) will be performed to assess your cognitive function and the Columbia Suicide Severity Rating Scale (C-SSRS) will be performed to assess if you have any suicidal thoughts/behaviour. You will be trained on how to complete the Parkinson's disease Diaries. The training will take 4 hours to complete.

After all of your test results have been received and reviewed, you will be notified whether or not you are qualified to continue to participate in the study.

Prior to Visit 1

The study staff will contact you 4 days prior to Visit 1 to remind you to complete the 3-day PD diaries. The day prior to Visit 1, the study staff will remind you to bring your completed 3-day PD diary.

Visit 1 (Week 0)

During Visit 1, the following procedures will be performed:

- **Measure Blood Pressure, Pulse, Breathing, and Temperature**
- **Collect and Review PD Diaries:** The study doctor will collect and review your PD Diaries which were given to you at Screening.
- **Complete Questionnaires**
- **Perform MDS-UPDRS assessment**
- **Dispense Study Drug:** The study doctor or a member of the study team will give you IR CD-LD study drug and tell you how to take it. He/ she will ask you to bring back all unused study drug at the next study visit. You will have to stop taking any CD (or benserazide)-LD containing prescriptions that you currently have at home or may receive during the course of this study.
- **Complete Health and Medication Questions:** The study staff will then ask you a series of questions regarding any medications that you are taking and any symptoms or side effects that you may have experienced.
- **Perform PD Diary Training and Dispense PD Diaries:** If you continue to qualify for the study, the study doctor will review the completion instructions with you and ask you to record how you feel at home every 30 minutes you are awake in a provided 24-hour diary for 3 days in a row (consecutive) immediately prior to Visit 2. He/ She will ask you to bring back your completed PD diaries at Visit 2.

If you continue to qualify for the study, the next study visit will be scheduled.

For the next 3 weeks, you will be contacted by the study staff regularly to evaluate your health status and determine whether dose adjustments are needed for the IR CD-LD study drug. However, you should be on the **same dose of IR CD-LD study drug for 5 days before Visit 2.**

Prior to each subsequent visits, the study staff will phone you to remind you to complete your 3-day PD diaries and to bring your completed diaries, any unused study drug and empty study drug bottles to the scheduled visit.

At Visit 2 (Week 3)

Visit 2 will occur approximately 3 weeks after Visit 1. The following procedures will take place:

- **Measure Blood Pressure, Pulse, Breathing, and Temperature**
- **Collect and Review PD Diaries**
- **Complete Health and Medication Questions**
- **Complete Questionnaires**
- **Perform MDS-UPDRS assessment**
- **Collect Unused Study Drug and Empty Study Drug Bottles:** The study doctor or study staff will collect any unused study drug and empty study drug bottles.
- **Dispense Study Drug:** You will be given IPX203 study drug and the site will instruct you on how to take the study drug.

If you continue to qualify for the study, the next study visit will be scheduled.

At Visit 3 – (Week 5)

Visit 3 will occur approximately 2 weeks after Visit 2. The following procedures will take place:

- **Measure Blood Pressure, Pulse, Breathing, and Temperature**
- **Complete Health and Medication Questions**
- **Complete Questionnaires**
- **Collect Unused Study Drug and Empty Study Drug Bottles**
- **Dispense Study Drug:** you will be given IPX203 study drug.
- **Dispense PD Diaries**

If you continue to qualify for the study, the next study visit will be scheduled.

After Visits 1, 2 and 3, the study staff will call you at regular intervals to evaluate your health status and to evaluate whether dose adjustments are needed for your study drug.

You should be on the **same IPX203 dosing regimen for at least 5 days prior to Visit 4.**

Visit 4 – (Week 7)

Visit 4 will occur approximately 2 weeks after Visit 3. During Visit 4, the following procedures will be performed:

- **Measure Blood Pressure, Pulse, Breathing, and Temperature**
- **Complete Questionnaires**
- **Review the PD Diaries**
- **Complete Health and Medication Questions**
- **Collect Unused Study Drug and Empty Study Drug Bottles**
- **Perform MDS-UPDRS assessment**
- **Dispense Study Drug:** IPX203 and IR CD-LD placebo or IR CD-LD and IPX203 placebo will be provided.
- **Dispense PD Diaries**

At Visit 5 (Week 10):

Visits 5 will occur approximately 3 weeks after Visit 4. The following procedures will be performed:

- **Measure Blood Pressure, Pulse, Breathing, and Temperature**
- **Measure weight**
- **Perform an ECG test**
- **Collect Blood and Urine samples for clinical laboratory studies**
- **Complete Questionnaires**
- **Review the PD Diaries**
- **Perform MDS-UPDRS assessment**
- **Complete Health and Medication Questions**
- **Collect Unused Study Drug and Empty Study Drug Bottles**
- **Dispense Study Drug:** You will receive your assigned study drug.
- **Dispense the PD Diaries**

At Visit 6 (Week 15):

Visit 6 will occur approximately 5 weeks after Visit 5. During Visit 6, the following procedures will be performed:

- **Measure Blood Pressure, Pulse, Breathing, and Temperature**
- **Complete Questionnaires**
- **Review the PD Diaries**
- **Perform MDS-UPDRS assessment**
- **Complete Health and Medication Questions**
- **Collect Unused Study Drug and Empty Study Drug Bottles**
- **Dispense Study Drug:** You will receive your assigned study drug.
- **Dispense the PD Diaries**

At Visit 7 (Week 20) This will be the End of Study Visit

Visit 7 will occur approximately 5 weeks after Visit 6. The following procedures will be performed:

- **Measure Blood Pressure, Pulse, Breathing, and Temperature**
- **Measure Weight**
- **Perform Physical Examination**
- **Perform an ECG test**
- **Collect Blood and Urine samples for clinical laboratory studies**
- **Complete Questionnaires**
- **Review the PD Diaries**
- **Perform MDS-UPDRS assessment**
- **Complete Health and Medication Questions**
- **Collect Unused Study Drug and Empty Study Drug Bottles**

At this time, the study doctor or your primary Parkinson's disease doctor may proceed to treat your Parkinson's disease as appropriate at his/her discretion.

Ask the study doctor or study staff for the estimated recovery time of your participation in this study.

Early termination:

If you discontinue the study prior to Visit 7, you will be asked to undergo the following procedures:

- **Measure Blood Pressure, Pulse, Breathing, and Temperature**
- **Measure Weight**
- **Perform Physical Examination**
- **Perform an ECG test**
- **Collect Blood and Urine samples for clinical laboratory studies**
- **Complete Questionnaires**
- **Collect the PD Diaries**
- **Perform MDS-UPDRS assessment**
- **Complete Health and Medication Questions**
- **Collect Unused Study Drug and Empty Study Drug Bottles**

See the schedule of events on the next page.

	Screening	3 Weeks of IR CD-LD Adjustment	4 Weeks of IPX203 Dose Conversion			13 Weeks of Double-Blind Therapy		
Visit Number		1	2	3	4	5	6	7 / Study Termination
Study Week	- 4	0	3	5	7	10	15	20
ICF Authorization	X							
Medical History	X							
Physical Examination	X							X
Vital Signs[a]	X	X	X	X	X	X	X	X
Height and Weight	X					X		X
Blood Tests and urine analysis	X					X		X
Urine Tests[b]	X							
Alcohol Breath Test	X							
ECG	X					X		X
PD Diary Training; Perform [c]	X	X	X	X	X	X	X	
Dispense PD Diaries	X	X		X	X	X	X	
Collection and Review of PD Diaries		X	X		X	X	X	X
Reminder Phone Calls[d]	X	X	X	X	X	X	X	X
Dispense Comparative Medication/ Study Drug		X	X	X	X	X	X	
Return of Empty Medication Bottles and Unused Comparative medication/Study Drug			X	X	X	X	X	X
Adverse Events	X	X	X	X	X	X	X	X
Concomitant Medication	X	X	X	X	X	X	X	X
Scales and Questionnaires[e]	X	X	X	X	X	X	X	X

a - Blood Pressure, pulse, breathing rate, and temperature will be measured. Your blood pressure and pulse will be taken in both lying down and standing positions.

b - A urine sample will be tested for drugs of abuse (recreational drugs). You are not allowed to take recreational drugs while participating in the study. The results of the urine drug tests must be negative in order for you to be in the study. If you are a woman and can have children, you will have a urine pregnancy test. The study doctor or study staff will tell you if the pregnancy test results are positive. The results of the pregnancy test must be negative in order for you to be in the study.

c - Parkinson's disease (PD) Diary: You will be instructed on how to complete a PD diary. At screening and on Visit 1 and 3-6, you will be given 3 diaries to take home with you and will be asked to record how you feel at home every 30 minutes you are awake in a provided 24-hour diary for 3 consecutive (back-to-back) days immediately prior to these visits to the clinical centre (Visits 1, 2 and 4, 5, 6, and 7). You will be asked to bring the completed diaries with you to Visits 1, 2, 4, 5, 6, and 7. Your PD Diary is extremely important to this study and is the primary data source enabling determination of the effectiveness of IPX203. Therefore, your timely and careful attention to completion of every PD Diary is critical to your continued participation in this study.

d - The study staff will contact you 4 days prior to Visit 1, 2, 4, 5, 6 and 7 to remind you to complete the 3-day PD diaries. The day prior to Visit 1, 2, 4, 5, 6 and 7 the study staff will remind you to bring your completed 3-day PD diary. You will also be called the day prior to Visit 2, 3, 4, 5, 6 and 7 to remind you to bring any unused comparative medication/study drug and empty comparative medication/study drug bottles to the upcoming Visits. For Visits 1 through 4 you will be contacted by the study staff throughout the IR CD-LD Adjustment and IPX203 Dose Conversion periods regularly to evaluate your health status and adjustments to the comparative medication/study drug regimen.

e – A number of questionnaires will be completed as part of this study by you or by the study staff. The study doctor or study staff can answer any questions you may have about the scales and questionnaires used in this study as well as any other tests and procedures done at each visit.

4. What do I have to do?

It is important for your own safety that you inform the study staff of your complete medical history and all medications/supplements/herbal preparations that you have taken over the past 30 days prior to the Screening Visit. You must also notify the study staff of any changes to your current medications during the study. If you notice any health problems, please notify the study staff immediately. You must always follow the instructions of the study staff.

You must not take any recreational drugs or be exposed to them (for example, 'passive smoking' of marijuana) throughout the entire study. A positive drug test result will lead to discontinuation from this study.

5. Do I have to take part in this research study?

Participation in any research study is voluntary. If you do not wish to take part, you don't have to. If you decide to take part and later change your mind, you are free to withdraw from the study at any stage.

Your decision whether to take part or not, or to take part and then withdraw, will not affect your relationship with the study doctor or clinical site and will not involve any penalty or loss of benefits to which you would be otherwise entitled.

Before you make your decision, a member of the research team will be available so that you can ask any questions about the research study. You can ask for any information you want. Sign the Informed Consent Form only if you agree to participate and only after you have had a chance to ask your questions and have received satisfactory answers. You will be given a copy of the signed Participant Information Sheet and Informed Consent Form to keep.

6. What are the alternatives to participation?

Your alternative is to choose not to participate in the study and continue treatment with your usual clinical team. Some of the treatment options for Parkinson's disease include medications such as: carbidopa/levodopa, entacopone, rasagiline and rotigotine. There are also surgical options (deep brain stimulation) for those who qualify. You should discuss your alternatives to participating in this research with the study staff. In addition, you may discuss your options with your GP.

7. What are the possible benefits of taking part?

Taking the study drug might help your Parkinson's disease but there is no guarantee that being in this study will help you. However, your participation in this study may help develop important scientific knowledge that could contribute to the development of a new drug product for Parkinson's disease.

8. What are the possible risks and disadvantages of taking part?

Experimental drugs often cause side effects. You may have none, some or all of the effects listed below, and they may be mild, moderate or severe. If you have any of these side effects, or are worried about them, or if you have questions about any of the signs and symptoms of any side effects that you read about in this consent form, talk with your study doctor. Your study doctor will also be looking out for side effects.

In the majority of instances of adverse events occurring in clinical studies of drugs for neurologic diseases, side effects go away shortly after dosing ends. However, sometimes, in rare instances, side effects can be serious, long lasting or permanent. If a serious side effect or reaction occurs, your study doctor may need to stop your participation in the study. Tell your study doctor right away if you have any problems with your health or the way you feel during the study, whether or not you think these problems are related to the study drug. He/she will discuss the best way of managing any side effects with you.

Uncommonly, there may be side effects that the researchers do not expect or do not know about and that may be serious, which could include your health getting worse. However, CD-LD-containing drugs for PD have been available in the UK and globally for over 30 years and therefore the benefits and potential side effects are well known. Tell your study doctor immediately about any new or unusual symptoms that you get. The treatment of the side effects will depend on the symptoms.

If participation in this study uncovers a medical condition of which you are unaware, the study doctors will discuss:

- whether you are suitable for the study; and
- whether you require referral to your GP or to a specialist.

What are the risks of taking IPX203 and IR CD-LD?

The most common adverse events reported in controlled clinical studies by people with PD after dosing with CD-LD-containing drugs include:

- dyskinesia (excessive abnormal motor movements)
- nausea
- dizziness
- vomiting
- headache
- insomnia
- abnormal dreams
- hallucinations (seeing or hearing things that are not real)
- confusion
- dry mouth
- anxiety
- constipation
- on-off phenomena
- orthostatic hypotension (low blood pressure upon standing)
- falling
- diarrhoea
- somnolence (sleepiness), including attacks of sleep while driving
- tremor
- impulse control disorder: potential to experience intense urges to gamble, spend money, binge eat, increased sexual urges, and other intense urges and the inability to control these urges
- elevated eye pressures in people with glaucoma

It is possible that taking IPX203 and/or IR CD-LD may change how your regular medications, vaccines, or supplements work. It is very important that you tell the study doctor about any medications, supplements, or vaccines before you take them during the study.

Could I have an allergic reaction?

Sometimes people have allergic reactions to drugs. If you have a very bad allergic reaction, you could die. Some things that happen during an allergic reaction that could be a sign or symptom of a life-threatening allergic reaction (anaphylaxis) are:

- a rash
- a fast pulse
- sweating

- a feeling of dread
- swelling around the eyes and mouth
- swelling of the throat
- wheezing
- having a hard time breathing
- a sudden drop in blood pressure (making you feel dizzy or lightheaded)
- inability to breathe without assistance

You should get medical help and contact the study doctor or study staff if you have any of these or any other side effects during the study.

If I stop or change when I take my regular medication, what are the risks?

If you stop or change when you take your regular medication to be in the study, your Parkinson's disease symptoms might come back or get worse, or your health might get worse. Please tell the study doctor or study staff right away if you have any problems when you stop or change your regular medication.

What are the risks of giving blood for this study?

Having blood taken from a vein may cause some discomfort, dizziness, or bruising. Sometimes, the blood vessel may swell, or blood may clot in the blood vessel, or the spot from which blood is taken could become swollen and red. Rarely, there could be a minor infection or bleeding. If this happens, it can be treated. You will be asked to give about 30 ml (approximately 2 tablespoons) of blood during the study.

Are there any other risks?

Filling out the questionnaires or answering the study doctor or study staff's questions could lead you to feel uncomfortable or upset. Please tell the study doctor or study staff if you feel uncomfortable or upset while filling out a questionnaire or answering questions. You have the right to refuse to answer any questions.

There is a risk of loss of confidentiality of your information. You will read more about the protection of your information later in this form. Please ask the study doctor or study staff if you would like to know more about how your information will be protected while you are in this study.

9. Contraception/Reproductive Risks:

The effects of IPX203 and IR CD-LD on the unborn child or a nursing infant are not known. If you are pregnant or nursing a child while taking IPX203 and IR CD-LD, there may be risks to you, the embryo, foetus or nursing child (or there may be risks to an unborn embryo or foetus you father during the study). For this reason, you should not father a child, donate sperm or become pregnant or begin breastfeeding during the study or for 6 weeks after completing the study. You must consent to use a medically acceptable method of contraception throughout your study participation and for 6 weeks after completing the study (described below).

For men

You must inform your female partner about your participation in the study. You should advise your study doctor immediately if you father a child while participating in the research study or for 30 days after your last dose of study drug. Your study doctor will advise on medical attention for your partner should this be necessary. The study doctor or study staff may ask for information about the pregnancy and the child's health at birth and may share this information with the sponsor.

Acceptable methods of contraception for you and/or your partner include the following:

- Abstinence
- Medically approved hormonal methods (discuss with the study doctor)
- Condom with partner using vaginal spermicide
- Diaphragm with vaginal spermicide
- Intrauterine device
- Surgical sterilisation (for more than 6 months)
- Female partner is post-menopausal (no menstrual period for more than 2 years)

If you are uncertain of what forms of contraception are acceptable for use during the study, please ask the study doctor.

For women

Because the drugs in this study may affect an unborn baby or nursing child, you should not be pregnant or become pregnant or begin breastfeeding while on this study and for 6 weeks following the end of the study.

You must confirm to the study doctor that, to the best of your knowledge, you are not pregnant now, and that you do not intend to become pregnant during the study.

Acceptable methods of contraception for you and/or your partner include the following:

- Abstinence
- Medically approved hormonal methods (discuss with the study doctor)
- Condom with partner using vaginal spermicide
- Diaphragm with vaginal spermicide
- Intrauterine device
- Surgical sterilisation (for more than 6 months)
- Post-menopausal (no menstrual period for more than 2 years)

If you suspect that you have become pregnant during the study or within 30 days of your last dose of study drug, you must notify your study doctor immediately. You will not be able to continue participation in the study if you become pregnant. The study doctor or study staff may ask for information about the pregnancy and the child's health at birth and may share this information with the sponsor.

10. What will happen to my test samples?

By consenting to take part in this study, you also consent to the collection and testing of your urine and blood samples for this research only.

The total volume of blood taken for the study could be up to approximately 30 ml (approximately 6 teaspoons) over 13 weeks. For comparison, a standard blood donation is approximately 450 mL (1 pint). The blood and urine samples collected for the assessment of your health status (for example, liver and kidney function tests) will be processed by a central lab. These samples will be labelled with your personal details (your participant number and your initials) and will be destroyed once the analysis is complete.

The urine samples collected for drugs of abuse and pregnancy testing (if applicable) will be kept at the study site until the results of these tests are available, and then will be destroyed.

If you change your mind later about being in the study, you can ask the study doctor or study staff about the destruction of your remaining identifiable samples. However data collected from already analysed samples will be kept as permitted by UK laws to preserve the scientific integrity of the study.

11. What if new information arises during this research study?

Sometimes during the course of a research study, new information becomes available that might change your mind about continuing in the study. If this happens, your study doctor will tell you about it and discuss with you whether you want to continue in the research study. If you decide to withdraw, your study doctor will make arrangements for your regular health care to continue. If you decide to continue in the research study, you will be asked to sign an updated Participant Information Sheet and Informed Consent Form.

Also, on receiving new information, your study doctor might consider it to be in your best interest to withdraw you from the research study. If this happens, he/she will explain the reasons and arrange for your regular health care to continue.

12. Can I have other treatments during this research study?

While you are participating in this research study, you may not be able to take any new medications or treatments. Your study doctor will review medications that are permitted and medications and procedures that are prohibited during the study. It is important to tell your study doctor and the study staff about any treatments or medications you may be planning to take or have taken, including over-the-counter medications, vitamins or herbal remedies, acupuncture or other alternative treatments.

13. What if I withdraw from this research study?

If you decide to withdraw from the study, please notify the study doctor or a member of the study staff before you withdraw. This notice will allow them to discuss any health risks or special requirements linked to withdrawing. You will be asked to return to the study clinic for an early termination study visit if you choose to withdraw from the study early.

If you do withdraw your consent during the research study, the study doctor and relevant study staff will not collect additional personal information from you, although personal information already collected will be retained and used to ensure that the results of the research study can be measured properly and to comply with the law, as further described below. You should be aware that data collected by the sponsor up to the time you withdraw will form part of the research study results.

Your participation may also be stopped without your consent if your study doctor feels that it is in your best interest. The sponsor, Impax Laboratories, LLC, can also stop this study at any time.

14. Could this study be stopped unexpectedly?

This research study may be stopped unexpectedly for a variety of reasons. These may include reasons such as:

- Unacceptable side effects
- Decisions made by the sponsor or by local regulatory/health authorities
- If the study doctor decides it is in the best interest of your health and welfare to stop.

You will be asked to return to the hospital for an early termination study visit if you are withdrawn from the study early.

15. What will happen when the research study ends?

You may be offered the opportunity to take part in an extension study in order to continue receiving the investigational drug IPX203.

Part 2: How is the research study being conducted?

16. What if I get hurt or sick while I am in this study?

If you get hurt or sick as a direct result of being in this study, Impax Laboratories, LLC will provide compensation for any injury caused by taking part in this study in accordance with the guidelines of the Association of the British Pharmaceutical Industry (ABPI). Impax will pay compensation where the injury most probably resulted from:

- IPX203, the drug being tested or administered as part of the trial protocol
- Any test or procedure you received as part of the study that is not part of the standard of care for your disease or condition or that would not have occurred but for your participation in this study.

Any payment would be without legal commitment. (Please ask if you wish more information on this.)

Impax is not be bound by these guidelines to pay compensation where:

- The injury resulted from a drug or procedure other than IPX203
- The protocol was not followed

- A test or procedure is part of the standard of care for your disease or condition or
- A test or procedure would have been received even if you had not participated in this study.

To ask questions about this, talk to the study doctor or study staff.

If you have personal insurance, your participation in this study may affect your policy. If necessary, before agreeing to take part in this study, you need to check this to ensure that your taking part does not affect your medical insurance or other personal insurance

You do not give up any of your legal rights by signing this form, except for a limited waiver of confidentiality explained below.

17. Who is organising and funding the research?

Impax Laboratories, LLC is the sponsor of this study, meaning that this company is organising and funding this research. Impax may benefit financially from this research study if, for example, the study assists Impax to obtain approval for a new drug.

By taking part in this research study, you agree that samples of your blood (or data generated from analysis of these materials) may be provided to Impax.

Impax may directly or indirectly benefit financially from your samples or from knowledge acquired through analysis of your samples.

In addition, if knowledge acquired through this research leads to discoveries that are of commercial value to Impax, the study doctors or their institutions, there will be no financial benefit to you or your family from these discoveries.

Will I be paid to take part in this research study?

No you will not be paid to take part in the study, however, reasonable and necessary travel expenses in connection with the study, will be reimbursed (against a receipt).

Will it cost anything to take part in this research study?

It is not anticipated that participation in this research study will result in any additional cost to you.

18. Further information and who to contact

You have the right to ask questions about the study at any time. During the study, the study doctor or a member of his/her staff will answer questions you may have about the study. Contact details of study doctor:

Name: Dr. Emer MacSweeney

If you have any questions about your rights as a study participant, or complaints about this research study, please contact the local PALS.
Contact details of PALS:

Name: Khadija Sheik
Contact telephone number: 020 3355 3536

19. What will happen to information about me?

Impax Laboratories, LLC ("Impax") is the sponsor for this study, and is based in the USA.

We will be using information from you and/or your medical records in order to undertake this study and related research and will act as the data controller for this study. This means that we are responsible for looking after your personal data and using it properly. Impax will keep identifiable information about you for 25 years after the study has finished (or longer, where doing so is either required by law, as part of inspections or legal disputes, or to support permissible future scientific research).

Health and care research should serve the public interest, which means that we have to demonstrate that our research serves the interests of society as a whole. We do this by following the UK Policy Framework for Health and Social Care Research.

We use personally-identifiable information to conduct research to improve health and care. As a pharmaceutical company we have a legitimate interest in using information relating to your health and care for research studies, when you agree to take part in a research study. This means that we will use your data, collected in the course of a research study, in the ways needed to conduct and analyse the research study. Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already obtained. To safeguard your rights, we will use the minimum personally-identifiable information possible.

If you wish to raise a complaint on how we have handled your personal data, you can contact our Data Protection Officer who will investigate the matter. If you are not satisfied with our response or believe we are processing your personal data in a way that is not lawful you can complain to the Information Commissioner's Office (ICO).

Impax's Data Protection Officer can be contacted at Amneal Pharmaceuticals, Inc., 400 Crossing Boulevard, Third Floor Bridgewater, NJ 08807 or at dataprivacy@amneal.com.

You can find out more about how Impax uses your information by contacting your hospital (NHS), or Impax's Data Protection Officer using the contact information above.

The hospital (NHS) will collect information from you and/or your medical records for this research study in accordance with our instructions. The hospital (NHS) will use your name, NHS number and contact details to contact you about the research study, and make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study. Individuals from Impax and regulatory organisations may look at your medical and research records to check the accuracy of the research study. The hospital (NHS) will pass these details to Impax along with the information collected from you and/or your medical records. The only people in Impax who will have access to information that identifies you will be people who need to contact you in exceptional circumstances, such as emergencies or legal disputes, or who need to audit the data collection process. The people who analyse the information will not be able to identify you and will not be able to find out your name, NHS number or contact details.

The hospital (NHS) will keep identifiable information about you from this study for 25 years after the study has finished (or longer, where doing so is either required by law, as part of inspections or legal disputes, or to support permissible future scientific research).

It might be necessary to share personal data with regulatory authorities and inspectors, other companies within the Amneal Pharmaceuticals group (for example, “parent” and "sister" companies of Impax), and other third parties (for example, a contract research organisation named Syneos Health, a lab testing provider named Eurofins, secure data storage and handling facilities, and external consultants and statisticians).

Those third parties might be in the UK/EEA, the USA, or elsewhere. Typically, when personal data is sent from the UK/EEA to a recipient somewhere else in the world, that recipient will have to legally commit to continue to protect your data, even abroad, in the same way your data would have been protected within the UK/EEA.

For example, when the hospital uploads "case report forms" (described below) to Impax's clinical trial data storage facilities in the USA, Impax has asked them to enter into a contract to protect that data. You can request further information by contacting your hospital or Impax's Data Protection Officer (see above).

ClinicalTrials.gov

A description of this clinical study will be available on http://www.ClinicalTrials.gov and https://www.clinicaltrialsregister.eu. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

Case Report Form (CRF)

Information about you may also be obtained from your medical records held at this, and other, health services for the purpose of this research. Any information taken from these records will be recorded on special forms ["CRF" or "electronic CRF" (eCRF)] by the study doctor and his/her study staff. These forms will contain your initials, participant number, your gender and birth date. Information from these forms will be in a computerised database managed by Impax or designee and will be part of the study results.

A copy of these forms will be kept by Impax for 25 years with all other study related documents.

Publications

No publication or public presentation about the research described in this Participant Information Sheet will reveal your identity.

Impax Laboratories, LLC, as the sponsor, would like to take this opportunity to thank you for the time you have taken to consider your participation in this study. Your potential contribution to this research will be greatly appreciated, and may help other patients in the future by helping researchers understand more about Parkinson's disease participants with motor fluctuations.

Re:Cognition Health
Brain and Mind Experts

INFORMED CONSENT FORM

Study Title: A Randomized Controlled Study To Compare The Safety And Efficacy Of IPX203 With Immediate –Release Carbidopa-Levodopa In Parkinson's Disease Patients With Motor Fluctuations

Study #: IPX203-B16-02

Sponsor: Impax Laboratories, LLC

IRAS No: 259840

Study Doctor: Dr. Steven Allder

Research Site: Re:Cognition Health - London

Research Address: 45 Queen Anne Street, London W1G 9JF

Telephone Number: 020 3355 3536

24 Hour Number: 07540802222

Participant's Name: _____

Participant's Number: _____

Please initial each box if you agree with the statement. You must initial all boxes to be eligible to take part in the study.

Your Consent	Please Initial)
1. I confirm I have read and understand the participant information sheet Version 1.1.0 dated 28 August 2019, for the above study and have had the opportunity to ask questions. I have been given enough time and opportunity to ask about the details of the research study and to decide whether or not to participate. I voluntarily agree to be in this study.	
2. I understand that my participation in this study is voluntary and that I am free to withdraw without giving any reason, without my medical care or legal rights being affected.	
3. I understand that relevant sections of my medical notes and data collected during the study may be looked at and shared by individuals from Impax (or other companies within the Amneal Pharmaceuticals group), regulatory authorities, or the hospital, and by people working on their behalf. I agree to set aside their duties of confidentiality, to the extent necessary for the purposes explained to me in the participant information sheet.	

4. I agree that my personal data may be transferred to other countries (for example, to U.S. regulatory authorities and to companies within the Amneal Pharmaceuticals group and their service providers outside the UK/EEA) in cases where it is not reasonably feasible to ensure that the data will receive substantially the same legal protection as in the UK.	
5. I agree to my GP being informed of my participation in the study.	

Aside from the limited waiver of confidentiality at row 3 above, I do not give up any of my legal rights by signing this consent document.

I have been told that I will receive a signed and dated copy of this document.

_____
Printed Name of Study Participant

_____ _____
Signature of participant Date (dd/mm/yyyy)

PERSON OBTAINING CONSENT

_____
Printed Name of the Person Conducting the Consent Discussion

_____ _____
Signature of the Person Conducting the Consent Discussion † Date of signature

† The investigator, or an appropriately qualified and trained person designated by the investigator to conduct the informed consent process, must sign and date the consent document during the same interview when the subject signs the consent document.

_____
Printed name of impartial witness ‡

_____ _____
Signature of impartial witness Date of signature§

☐ Not applicable (*Check this box if the Signature of an impartial witness is not required. Signature of an impartial witness is required if the subject or subject's legal representative cannot read.*)

‡ Impartial Witness: A person, who is independent of the study, who cannot be unfairly influenced by people involved with the study, who attends the informed consent process if the subject or the subject's legal representative cannot read, and who reads the informed consent and any other written information supplied to the subject. Guidance for Industry E6 Good Clinical Practice: Consolidated G

Note: All parties signing the consent section must date their own signature.

When completed, 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes